insights_auto
Miks on DEVA langenud? 2,33%?
Uurige põhjalikumaltchevron_right
DEVA:IST
Deva Holding AS
83,85 TRY
arrow_downward
−2,33%(−2,00) 1 p
12. okt, 10:48:32 GMT +3 · TRY
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse DEVA põhistatistika genereerimine…
Ava
85,85 TRY
Kõrge
86,25 TRY
Madal
83,50 TRY
Turu kapit.
16,77 mld
Keskm. maht
660,43 tuh
Maht
126,79 tuh
52 näd kõrgeim
109,30 TRY
52 näd madalaim
57,50 TRY
Aktsiatulu
−4,21 TRY
Käibivad aktsiad
200,02 mln
Töötajate arv
3 tuh
Ava
85,85 TRY
Kõrge
86,25 TRY
Madal
83,50 TRY
Turu kapit.
16,77 mld
Keskm. maht
660,43 tuh
Maht
126,79 tuh
52 näd kõrgeim
109,30 TRY
52 näd madalaim
57,50 TRY
Aktsiatulu
−4,21 TRY
Käibivad aktsiad
200,02 mln
Töötajate arv
3 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
CryptoRank
·
41 minuti eest
TruGolf completes Polymath acquisition, bringing tokenization infrastructure into Nasdaq-listed company
TradingView
·
1 tunni eest
Key facts: Goldman, Barclays Back NASDAQ:PLTR; CTO Defends Maven AI
Bloomberg.com
·
33 minuti eest
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profiil
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
Teave üksuse Deva Holding AS kohta